复方斑蝥胶囊联合TAC方案治疗三阴性乳腺癌的临床研究
Clinical study on Compound Banmao Capsules combined with TAC regimen in treatment of triple negative breast cancer
周国平 1许淑华 1范慧文2
作者信息
- 1. 东台市中医院 普外科,江苏 盐城 224200
- 2. 盐城市第一人民医院 乳腺外科,江苏 盐城 224006
- 折叠
摘要
目的 探讨复方斑蝥胶囊联合TAC方案治疗三阴性乳腺癌的疗效.方法 选取2020 年4 月—2023年 3 月在东台市中医院就诊的 100 例三阴性乳腺癌患者,根据随机数字表法将 100 例患者分为对照组(50 例)和治疗组(50 例).对照组给予TAC方案治疗,第 1 天静脉注射多西他赛注射液 75 mg/m2、静脉滴注注射用环磷酰胺 600 mg/m2、静脉注射注射用盐酸表柔比星 80 mg/m2.治疗组在对照组基础上口服复方斑蝥胶囊,3 粒/次,2 次/d.以 21 d为 1 个化疗周期,两组在持续治疗 6 个周期后分析疗效.比较两组的临床疗效、生活质量、淋巴细胞相关指标、肿瘤标志物、血清指标和不良反应的情况.结果 治疗后,治疗组的总有效率(94.00%)高于对照组(80.00%),组间比较差异显著(P＜0.05).治疗后,两组的乳腺癌生活质量量表(QLSBC)评分低于治疗前(P＜0.05),且治疗组QLSBC评分低于对照组(P＜0.05).治疗后,治疗组的CD8+比治疗前小,LMR、CD4+、CD4+/CD8+比治疗前大(P＜0.05);治疗组的CD8+比对照组小,LMR、CD4+、CD4+/CD8+比对照组大(P＜0.05).治疗后,两组的血清糖蛋白抗原(CA153)、癌胚抗原(CEA)水平均比治疗前低(P＜0.05);治疗组血清CA153、CEA水平比对照组低(P＜0.05).治疗后,两组的血清脂联素(ADP)水平高于治疗前,血清白细胞介素-8(IL-8)水平低于治疗前(P＜0.05);治疗组的血清ADP水平高于对照组,血清IL-8 水平低于对照组(P＜0.05).治疗期间,治疗组的不良反应发生率比对照组低,组间比较差异显著(P＜0.05).结论 复方斑蝥胶囊联合 TAC 方案有助于提高三阴性乳腺癌的疗效,有助于改善患者的免疫功能和生活质量,降低肿瘤标志物的水平和药物不良反应的发生.
Abstract
Objective To investigate the efficacy of Compound Banmao Capsules combined with TAC regimen in treatment of triple negative breast cancer.Methods Patients(100 cases)with triple negative breast cancer in Dongtai Hospital of TCM from April 2020 to March 2023 were divided into control and treatment groups according to the random number table method,and each group had 50 cases.Patients in the control group was treated with TAC regimen.On the first day,patients in the control group received intravenous injection of 75 mg/m2 of Docetaxel Injection,intravenous drip of 600 mg/m2 of Cyclophosphamide for injection,and intravenous injection of 80 mg/m2 of Epirubicin Hydrochloride Injection.Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of the control group,3 grains/time,twice daily.One chemotherapy cycle had 21 days,and the efficacy of the two groups was analyzed after continuous treatment for 6 cycles.The clinical efficacies,Quality of life,lymphocyte r elated indicators,tumor markers and serum indicators,and adverse reactions in two groups were compared.Results After treatment,the total effective rate of the treatment group(94.00% )was higher than that of the control group(80.00% ),and the difference between groups was significant(P<0.05).After treatment,the QLSBC score of breast cancer in two groups was lower than that before treatment(P<0.05),and the QLSBC score in the treatment group was lower than that in the control group(P<0.05).After treatment,CD8+ in the treatment group was smaller than before treatment,but LMR,CD4+,CD4+/CD8+ were larger than those before treatment(P<0.05).CD8+ in the treatment group was smaller than that in the control group,while LMR,CD4+,CD4+/CD8+ were larger than those in the control group(P<0.05).After treatment,the serum levels of CA153 and CEA in two groups were lower than those before treatment(P<0.05).The serum levels of CA153 and CEA in the treatment group were lower than those in the control group(P<0.05).After treatment,the serum levels of ADP in two groups were higher than those before treatment,but the serum levels of IL-8 were lower than before treatment(P<0.05).The serum level of ADP in the treatment group was higher than that in the control group,but the serum level of IL-8 was lower than that in the control group(P<0.05).During the treatment period,the incidence of adverse reactions in the treatment group was lower than that in the control group,and there was a significant difference between the groups(P<0.05).Conclusion Compound Banmao Capsules combined with TAC regimen is helpful to improve the efficacy of triple negative breast cancer,improve the immune function and quality of life of patients,reduce the level of tumor markers,and reduce the occurrence of adverse drug reactions.
关键词
复方斑蝥胶囊/TAC方案/多西他赛注射液/注射用环磷酰胺/盐酸表柔比星注射液/三阴性乳腺癌/QLSBC评分/糖蛋白抗原/癌胚抗原/脂联素/白细胞介素-8Key words
Compound Banmao Capsules/TAC scheme/Docetaxel Injection/Cyclophosphamide for injection/Epirubicin Hydrochloride Injection/triple negative breast cancer/QLSBC score/CA153/CEA/ADP/IL-8引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据